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nant) relative to the total number of patients on whom EUS-
FNA was performed. Sensitivity was defined as the number 
of patients in whom EUS-FNA made a biopsy-proven diag-
nosis of malignancy relative to the total number of patients 
in whom the tumor was found to be malignant. We per-
formed a random-effects meta-analysis.  Results: Of 3,320 
search results, 11 studies were included. Ten had a high risk 
of bias. The total number of patients was 313; the proportion 
of patients with malignancy ranged from 87 to 100% across 
these studies. The average yield was 0.90 (95% CI 0.82–0.95) 
and the average sensitivity was 0.92 (0.83–0.96). In the sub-
group of prospective studies ( n = 3), the average yield was 
0.80 (0.56–0.93) and the average sensitivity was 0.83 (0.58–
0.95). EUS-FNA-induced complications were reported for 
5/256 patients (2.0%) for whom this information was avail-
able.  Conclusions: Although the number of high-quality 
studies is limited, these findings suggest that EUS-FNA is safe 
and has a high yield for diagnosing intrapulmonary tumors. 
 © 2016 The Author(s)
Published by S. Karger AG, Basel 
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 Abstract 
 Background: Biopsy-based diagnosis in patients with para-
esophageal intrapulmonary tumors suspected of lung can-
cer is crucial for adequate treatment planning.  Objective: To 
evaluate the performance of transesophageal endoscopic 
ultrasound-guided fine-needle aspiration (EUS-FNA) in the 
diagnosis of intrapulmonary tumors located near or adja-
cent to the esophagus.  Methods: We performed a system-
atic review (PROSPERO, CRD42016033737) and searched 
MEDLINE, Embase, BIOSIS Previews, and Web of Science on 
September 22, 2016, without date or language restrictions. 
We included studies that evaluated the yield and/or sensitiv-
ity of EUS-FNA for diagnosing intrapulmonary tumors. Yield 
was defined as the number of patients in whom EUS-FNA 
made a biopsy-proven diagnosis (malignant or nonmalig-
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 Introduction 
 Lung cancer is the number one cause of cancer-related 
mortality in the world  [1] . Accurate biopsy-based diagno-
sis of intrapulmonary tumors in patients suspected of 
lung cancer is crucial for adequate planning of treatment. 
In patients with centrally located lesions, clinical guide-
lines recommend conventional flexible bronchoscopy to 
obtain a tissue diagnosis  [2] . However, this technique is 
not feasible or nondiagnostic in a substantial proportion 
of patients, especially in the absence of endobronchial ab-
normalities  [2] . Other, more recently established options 
involve linear endobronchial ultrasound with real-time 
guided transbronchial needle aspiration (EBUS-TBNA) 
for intrapulmonary tumors located in close proximity to 
the major airways  [3, 4] , and navigational bronchoscopy 
or radial EBUS-TBNA for peripherally located tumors  [5, 
6] . However, each of these techniques requires the tumor 
to be located near an airway, which is not always the case. 
In those cases, computed tomography (CT)-guided trans-
thoracic needle aspiration is sometimes used, but it is un-
attractive because of a substantial risk of pneumothorax 
and hemoptysis  [7] .
 In patients in whom CT imaging shows that the intra-
pulmonary tumor is located near or adjacent to the esoph-
agus, transesophageal endoscopic ultrasound-guided 
fine-needle aspiration (EUS-FNA) may provide a valuable 
minimally invasive alternative (see  Fig. 1 and case exam-
ple in Box 1)  [8–10] . The role of EUS-FNA in mediastinal 
nodal staging in patients with proven or suspected lung 
cancer is well established and part of the current clinical 
guidelines  [11–15] . However, its performance in obtain-
ing an adequate tissue sample directly from intrapulmo-
nary tumors has received much less attention  [8, 10] .
 EUS-FNA is a safe and inexpensive procedure, espe-
cially if the alternative for obtaining a tissue diagnosis is 
surgery. Therefore, if sufficiently feasible, it is likely to be 
a useful test in the diagnosis of intrapulmonary tumors, 
not only after a nondiagnostic bronchoscopy but also as 
the first invasive test to be applied in the diagnostic work-
up of patients with suspected lung cancer. A major advan-
tage would be that biopsies from the intrapulmonary tu-
mor, and biopsies for staging purposes from the medias-
tinum or other areas, can be taken in a single session  [9] .
 The yield and sensitivity of EUS-FNA for diagnosing 
intrapulmonary tumors located near or adjacent to the 
esophagus are not well established  [8] , and they can be 
negatively impacted during different steps of the proce-
dure: the tumor may not be visualized by EUS; if visual-
ized, it may not be possible to take a biopsy; and if biop-
sied, the material may not be representative. In each of 
these cases, EUS-FNA can be considered as nondiagnos-
tic, and additional testing would be needed to establish a 
tissue diagnosis.
 We performed a systematic review and meta-analysis 
to obtain summary estimates of the yield and sensitivity 
of EUS-FNA for diagnosing intrapulmonary tumors lo-
cated near or adjacent to the esophagus in patients with 
suspected lung cancer.
 Material and Methods 
 The protocol of this systematic review was prospectively regis-
tered at PROSPERO under registration No. CRD42016033737.
 Fig. 1. Intrapulmonary tumors (T) that cannot be reached from the 
major airways may be biopsied from the esophagus. EUS, endo-
scopic ultrasound. 
 Korevaar/Colella/Spijker/Bossuyt/Konge/
Clementsen/Annema
 
Respiration 2017;93:126–137
DOI: 10.1159/000452958
128
 Eligibility Criteria 
 Studies were included if they evaluated the yield and/or sensi-
tivity of EUS-FNA for diagnosing intrapulmonary tumors located 
near or adjacent to the esophagus in patients with suspected lung 
cancer, where the aim was to obtain a tissue sample from the in-
trapulmonary tumor. Studies were eligible regardless of whether 
they selected patients based on the results of previous tests or based 
on tumor size. Both prospective and retrospective studies were 
 eligible.
 We also included studies if they aimed to obtain a tissue diag-
nosis from intrapulmonary tumors invading the mediastinum or 
central vessels, but we excluded studies that focused on diagnosing 
mediastinal tumors, as well as studies that aimed to diagnose an 
intrapulmonary tumor by sampling metastases in, for example, the 
mediastinum, liver, or adrenal gland.
 We also excluded studies that focused on T-, N-, or M-staging 
rather than on diagnosing intrapulmonary tumors, studies that fo-
cused on EBUS-TBNA instead of EUS-FNA, studies using radial 
instead of linear EUS equipment, and studies that aimed to sample 
an intrapulmonary tumor in fewer than 10 patients.
 Search and Selection 
 The literature searches on MEDLINE, Embase, BIOSIS Pre-
views, and Web of Science were developed by a medical informa-
tion specialist (R.S.). The complete search strategy is provided in 
online supplementary material A (for all online suppl. material, see 
www.karger.com/doi/10.1159/000452958). No date or language 
restrictions were applied. The final searches were performed on 
September 22, 2016.
 The titles and abstracts of the search results were examined by 
2 independent investigators (D.A.K. and S.C.). If an article was 
considered potentially eligible by one of them, they independently 
assessed the corresponding full article for inclusion, with disagree-
ments being resolved by discussion. If necessary, a third investiga-
tor (J.T.A.) made the final decision.
 To identify additional relevant publications, 1 investigator 
(D.A.K.) screened the reference lists of the included articles, and 
all articles citing them (through Google Scholar). To identify un-
published studies, this investigator also screened ClinicalTrials.
gov and the WHO International Clinical Trials Registry Platform 
Search Portal, without time limits. These additional searches were 
performed on March 24, 2016.
 Data Extraction 
 One investigator (D.A.K.) extracted data from all the included 
studies; data extraction was verified by a second investigator (S.C.). 
We extracted the first author, year of publication, journal, and 
country of patient recruitment. We also recorded whether or not 
patients had undergone previous (nondiagnostic) tests to obtain a 
tissue sample of the intrapulmonary tumor, and whether or not 
there were any restrictions with regard to the location or size of the 
tumor in the inclusion criteria. We then extracted details about age 
and gender, the type of test under evaluation (EUS with an endo-
scope vs. EUS-B with an EBUS-scope), the experience of the 
endoscopist(s), the availability of rapid on-site cytological evalua-
tion, the needle type, the number of needle passes performed, pro-
cedure length, tumor size, the reference standard, and any compli-
cations from EUS-FNA.
 We also extracted the total number of patients on whom EUS-
FNA was performed with the aim of diagnosing an intrapulmo-
nary tumor, the number of patients in whom the tumor could be 
visualized by EUS, the number of patients from whom an adequate 
tissue sample could be obtained by EUS-FNA, the number of pa-
tients in whom EUS-FNA made a correct biopsy-proven diagnosis 
(malignant or nonmalignant), the number of patients in whom 
EUS-FNA diagnosed a malignancy, and the number of patients in 
whom the targeted intrapulmonary tumor turned out to be malig-
nant, as determined by the reference standard.
Case 
example:
A 66-year-old smoker presented with a 
centrally located intrapulmonary tumor in the 
left upper lobe on a CT scan (Image A). 
Conventional bronchoscopy and EBUS-TBNA 
were nondiagnostic. CT-guided transthoracic 
needle aspiration only showed necrotic tissue 
(Image B). During EUS, the tumor was clearly 
visualized, and FNA was performed, which 
showed squamous cell carcinoma (Image C). 
EUS-FNA, endoscopic ultrasound-guided fine-
needle aspiration; CT, computed tomography; 
EBUS-TBNA, endobronchial ultrasound with 
real-time guided transbronchial needle 
aspiration.
Image A:
Image B:
Image C:
 Box 1. EUS-FNA for diagnosing intrapulmonary tumors after a 
nondiagnostic bronchoscopy
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 We considered EUS-FNA to have made an incorrect diagnosis 
if a subsequently performed reference standard resulted in a dif-
ferent diagnosis, or if EUS-FNA was nondiagnostic so that further 
invasive procedures were needed to arrive at a diagnosis. We con-
sidered EUS-FNA to have made a correct diagnosis of malignancy 
if the tissue material contained malignant cells. We did so because 
a reference standard is rarely performed in such cases and false-
positive EUS-FNA findings are known to be rare.
 Quality Assessment 
 Two reviewers (D.A.K. and S.C.) independently assessed the 
risk of bias in each of the studies included, using the QUADAS-2 
tool  [16] ; here, as well, disagreements were resolved by consensus. 
If necessary, a third investigator (P.M.B.) made the final decision.
 Study design features associated with a high risk of bias were: 
(1) retrospective (nonconsecutive) inclusion of patients; (2) exclu-
sion of patients in whom the intrapulmonary tumor could not be 
visualized by EUS; (3) a case-control design; (4) endoscopists that 
were not blinded to the final diagnosis of the intrapulmonary tu-
mor while performing the procedure; (5) a suboptimal reference 
standard for patients with a nondiagnostic or nonmalignant EUS-
FNA (e.g., clinical follow-up); (6) partial verification of included 
patients with a nondiagnostic or nonmalignant EUS-FNA, mean-
ing that some of these patients did not receive a reference standard; 
(7) differential verification of patients with a nondiagnostic or 
nonmalignant EUS-FNA, meaning that some patients received an 
optimal reference standard, but others received a suboptimal refer-
ence standard; and (8) exclusion of patients with missing reference 
standard results.
 The QUADAS-2 tool can also be used to analyze concerns 
about applicability, but these were not taken into account, as such 
concerns were avoided by narrowing our inclusion criteria – for 
example, by excluding studies that used radial instead of linear 
EUS equipment.
 Primary Outcomes 
 The primary outcome measures in this review were: (1) the 
yield of EUS-FNA for diagnosing intrapulmonary tumors and (2) 
the sensitivity of EUS-FNA for diagnosing malignant intrapulmo-
nary tumors.
 Yield was defined as the number of patients in whom EUS-FNA 
made a correct biopsy-proven diagnosis (nonmalignant or malig-
nant) relative to the total number of patients on whom EUS was 
performed with the aim of diagnosing an intrapulmonary tumor.
 Sensitivity was defined as the number of patients in whom 
EUS-FNA made a correct biopsy-proven diagnosis of any malig-
nancy relative to the total number of patients in whom the target-
ed intrapulmonary tumor turned out to be malignant.
 Analysis 
 For each included study, we calculated estimates of yield and 
sensitivity, together with 95% CIs, using the normal approxima-
tion. We then performed a univariate random-effects meta-analy-
sis according to DerSimonian-Laird where proportions were logit 
transformed  [17] to produce summary estimates of yield and sen-
sitivity.
 We calculated  I 2 statistics to assess the extent of heterogeneity; 
an  I 2 statistic >50% is a rough indicator of substantial heterogeneity 
 [18] . Sources of heterogeneity were taken into account by perform-
ing subgroup analyses if at least 3 studies per subgroup were avail-
able. We focused on 2 potential methodological sources of hetero-
geneity that are likely to be associated with a major risk of bias: (1) 
the type of study (retrospective vs. prospective) and (2) explicitness 
in reporting of the total number of patients in whom the tumor 
could be visualized by EUS (not reported or unclear vs. explicitly 
reported). The latter subgroup analysis was performed because it 
was unclear for several studies whether patients in whom the tumor 
could not be visualized by EUS were excluded from the analysis. Ex-
cluding such patients leads to overestimation of test performance.
Excluded after 2 authors independently assessed full texts
(n = 127)
- Duplicate/erratum (n = 6)
- Conference abstract corresponding to published study (n = 10)
- Conference abstract with insufficient data to determine eligibility (n = 8)
- Editorial, news item, letter, or review (n = 19)
- No (linear) EUS (n = 1)
- Mediastinal staging, or diagnosis of mediastinal tumor not originating
   from the lungs (n = 41)
- Fewer than 10 intrapulmonary tumors, or results for intrapulmonary
   tumors not separately reported from other types of tumors (n = 29)
- T4 staging (n = 2)
- No tissue sampling involved, or no reference standard performed (n = 11)
- Embase (n = 1,994)
- MEDLINE (n = 1,522)
- BIOSIS Previews (n = 311)
- Web of Science (n = 1,003)
Excluded after 2 authors independently assessed titles and abstracts
(n = 3,183)
Potentially eligible articles
(n = 137)
Search results after deduplication
on September 22, 2016
(n = 3,320)
Diagnostically accurate studies
included (n = 11)
Unpublished study report obtained
through personal communication
(accepted for publication)
(n = 1)
 Fig. 2. Selection of studies. 
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 Four potential clinical sources of heterogeneity were defined: (1) 
previous tests had been performed to obtain a tissue sample of the 
intrapulmonary tumor and they were nondiagnostic (yes vs. no); (2) 
the size of the intrapulmonary tumor (as reported in the included 
studies); (3) the type of scope used (EUS vs. EUS-B); and (4) the 
availability of rapid on-site cytological evaluation (yes vs. no).
 Data analysis was performed using the “meta” package in R ver-
sion 3.0.
 Results 
 Study Selection 
 The electronic searches yielded 3,320 search results, 
from which 10 studies were included  [19–28] . Two of 
these included studies were conference abstracts  [21, 26] . 
Through personal communication, we were also able to 
include 1 additional study for which the report had been 
accepted for publication at the time of our searches but 
which had not yet been published  [29] .  Figure 2 provides 
the details of the study selection process, with reasons for 
excluding studies. Screening reference lists, citing arti-
cles, and trial registries did not reveal any additional rel-
evant studies.
 Study Characteristics 
 The detailed characteristics of the 11 studies included 
are reported in  Table 1 . These studies were published over 
a 12-year period – the first in 2004 and the last in 2016. In 
3 studies, all the included patients had undergone a previ-
ous nondiagnostic test such as conventional bronchos-
copy to obtain a tissue sample of the intrapulmonary tu-
mor, while in 3 other studies, only some patients had had 
a previous nondiagnostic test, and in 1 study, none of the 
patients had undergone previous testing to obtain a biop-
sy-based diagnosis. Information about previous testing 
was not reported in the remaining 4 studies. For most 
studies, it was unclear whether there were any restrictions 
with regard to the location or size of the tumor ( Table 2 ).
 The mean or median age of the patients ranged from 
58 to 68 years, and the ratio of male patients ranged from 
44 to 97%. The type of test was EUS in 10 studies and 
EUS-B in 1 study. None of the studies reported on the 
 experience of the endoscopist. Rapid on-site cytological 
evaluation was available in 7 studies, unavailable in 1 
study, and not reported in 3 studies.
 Most studies ( n = 8) used a 22-G needle. The mean or 
median number of needle passes ranged from 1 to 5 in the 
7 studies that reported this information. The median 
length of the procedure was 21 min in one study, with a 
mean length of 27 min in another study; this information 
was not reported in the remaining 9 studies. The mean or 
median long axis of the targeted tumor ranged from 26 to 
50 mm.
 Study Quality 
 Detailed results of the quality assessment of the studies 
included are provided in online supplementary material 
B. All but 1 study had at least 1 item with a high risk of 
bias. The most common source of bias was retrospective 
inclusion of patients, which was the case in 8 studies. In 6 
studies, it was unclear whether they excluded patients 
 Table 2. Definitions of targeted intrapulmonary tumors
Study [Ref.], 
year
Targeted intrapulmonary tumors were defined 
as…
Varadarajulu 
[19], 2004
“lung mass [adjacent to or abutting the 
esophagus] that was either confined to the lung 
parenchyma or was invading the mediastinum”
Annema [20], 
2005
“[intrapulmonary] tumor located near (<1 cm) 
or adjacent to the esophagus”
Paquin [21], 
2005
“lung masses accessible through the esophagus”
Sawhney [22], 
2006
“primary lung tumors that abutted or invaded 
the mediastinum”
Hernandez [23], 
2007
“masses that resided within the lung 
parenchyma and were adjacent to or abutting 
the esophagus”
Nguyen [24], 
2011
“lung lesions”
Songür [25], 
2011
“pulmonary masses invading the mediastinum”
Assisi [26], 2013 “pulmonary localization of disease”; 
“localized in dorsal superior segments”
Vazquez-
Sequeiros [27], 
2013
“lung masses […] with the closest margin 
believed to be in sufficient proximity to the 
esophageal wall”; “lung masses were located in 
the vicinity of the cervical/upper esophagus 
(n = 19; each <1 cm from esophagus) or mid 
esophagus (n = 43; each <2 cm from the 
esophagus)”
Nasir [28], 2014 “lung mass suspicious for either a primary or 
secondary neoplasm of the lung”; “mean 
distance between lesion and esophagus: 25 mm 
(range 0 – 46)”
Steinfort [29], 
2016
“pulmonary parenchymal lesions […] adjacent 
to the esophagus on Computed Tomography of 
the chest”
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from the analysis in whom intrapulmonary tumors could 
not be visualized by EUS. Four studies used a suboptimal 
reference standard in at least some of the patients, and 2 
studies excluded patients due to missing reference stan-
dard results.
 Diagnostic Yield and Sensitivity 
 Estimates of yield and sensitivity for the individual 
studies are reported in  Table 3 . The total number of pa-
tients with intrapulmonary tumors included in this re-
view was 313; the number ranged from 11 to 73 across 
individual studies. The great majority of patients turned 
out to have a malignancy, with proportions ranging from 
87 to 100% (median 100%). The final diagnoses of intra-
pulmonary tumors are provided in  Table 4 .
 The yield of EUS-FNA for diagnosing intrapulmonary 
tumors ranged from 0.68 to 1.00 across the included stud-
ies. The average yield after meta-analysis was 0.90 (95% 
CI 0.82–0.95;  I 2 = 55%) ( Fig. 3 ).
 The sensitivity of EUS-FNA for diagnosing malignant 
intrapulmonary tumors ranged from 0.67 to 1.00 across the 
included studies, but it could not be calculated for 2 studies, 
as these did not report the total number of patients that had 
a malignant tumor. The average sensitivity after meta-anal-
ysis was 0.92 (95% CI 0.83–0.96;  I 2 = 53%) ( Fig. 4 ).
 Sources of Methodological and Clinical Heterogeneity 
 In the 7 studies that were considered to have a high risk 
of bias because they were retrospective, the average yield 
for diagnosing intrapulmonary tumors was 0.93 (95% CI 
0.86–0.96;  I 2 = 32%) ( Fig. 3 ), and the average sensitivity for 
diagnosing malignant intrapulmonary tumors was 0.95 
(95% CI 0.90–0.98;  I 2 = 0%) ( Fig. 4 ). As expected, this was 
lower – though the difference was not statistically signifi-
cant – for the 3 prospective studies, for which these aver-
ages were 0.80 (95% CI 0.56–0.93;  I 2 = 65%;  p = 0.11) and 
0.83 (95% CI 0.58–0.95;  I 2 = 66%;  p = 0.06), respectively.
 Six studies were considered to have a high risk of bias 
because it was unclear whether EUS had been able to vi-
sualize the tumor in all patients included, or whether the 
patients in whom this was not possible were excluded 
from the analysis ( Table 3 ). In these studies, the average 
yield was 0.93 (95% CI 0.80–0.98;  I 2 = 47%), and the aver-
age sensitivity was 0.91 (95% CI 0.82–0.96;  I 2 = 9%). The 
other 5 studies explicitly reported in how many of the pa-
tients EUS was unable to visualize the tumor, which var-
ied from 16 to 0% ( Table 3 ). In these studies, the average 
yield and average sensitivity were comparable to those 
from studies for which this information was unclear, i.e., 
0.89 (95% CI 0.76–0.95;  I 2 = 68%;  p = 0.56) and 0.90 (95% 
CI 0.61–0.98;  I 2 = 81%;  p = 0.87), respectively.
 Table 3. Yield and sensitivity of EUS-FNA for diagnosing intrapulmonary tumors located near or adjacent to the esophagus
Study [Ref.], year Type of study Total EUS 
performed, 
n
Total with any 
malignancy,
n (%)
Tumor 
visualized 
by EUS, 
n (%)
Adequate tissue 
sample by 
EUS-FNA,
n (%)
Correct 
diagnosis by 
EUS-FNA,
n
Correct diagnosis 
of any malignancy 
by EUS-FNA, n
Yield for correct 
diagnosisb
(95% CI)
Sensitivity for 
malignancyc
(95% CI)
Varadarajulu [19], 2004a Retrospective 18 18 (100) 18 (100) 18 (100) 18 18 1.00 (0.69 – 1.00) 1.00 (0.69 – 1.00)
Annema [20], 2005 Prospective 32 32 (100) 32 (100) 31 (97) 31 31 0.97 (0.81 – 1.00) 0.97 (0.81 – 1.00)
Paquin [21], 2005a Retrospective 15 13 (87) 15 (100) 15 (100) 14 12 0.93 (0.65 – 0.99) 0.92 (0.61 – 0.99)
Sawhney [22], 2006 Prospective 19 18 (95) 16 (84) 16 (84) 13 12 0.68 (0.45 – 0.85) 0.67 (0.43 – 0.84)
Hernandez [23], 2007a Retrospective 17 17 (100) 17 (100) 17 (100) 17 17 1.00 (0.68 – 1.00) 1.00 (0.68 – 1.00)
Nguyen [24], 2011 Retrospective 24 NR 24 (100) 24 (100) 23 NR 0.96 (0.76 – 0.99) –
Songür [25], 2011a Prospective 22 20 (91) 22 (100) 17 (77) 16 16 0.73 (0.51 – 0.87) 0.80 (0.57 – 0.92)
Assisi [26], 2013a Retrospective 11 11 (100) 11 (100) 11 (100) 11 11 1.00 (0.58 – 1.00) 1.00 (0.58 – 1.00)
Vazquez-Sequeiros [27], 
2013
Retrospective 73 NR 62 (85) 61 (84) 60 NR 0.82 (0.72 – 0.89) –
Nasir [28], 2014 Retrospective 55 55 (100) 55 (100) 52 (95) 52 52 0.95 (0.84 – 0.98) 0.95 (0.84 – 0.98)
Steinfort [29], 2016a Retrospective 27 27 (100) 27 (100) 27 (100) 26 26 0.96 (0.78 – 0.99) 0.96 (0.78 – 0.99)
NR, not reported; EUS-FNA, endoscopic ultrasound-guided fine-needle aspiration.
a Unclear whether EUS had been able to visualize the tumor in all patients included, or whether the patients in whom this was not possible were excluded from the analysis.
b Yield was calculated as the number of patients in whom EUS-FNA made a correct biopsy-proven diagnosis (nonmalignant or malignant) divided by the total number of patients 
in whom EUS was performed with the aim of diagnosing an intrapulmonary tumor.
c Sensitivity was calculated as the number of patients in whom EUS-FNA made a correct biopsy-proven diagnosis of a malignancy divided by the total number of patients in whom 
the targeted intrapulmonary tumor turned out to be malignant.
 Esophageal Endosonography for 
Intrapulmonary Tumors 
Respiration 2017;93:126–137
DOI: 10.1159/000452958
133
 Table 4. Final diagnoses of intrapulmonary tumors
Study [Ref.], 
year
Total EUS
performed, n
Final diagnosis: any malignancy, n Final diagnosis: benign, n Final diagnosis of missed or incorrect 
diagnosis by EUS-FNA, n
Varadarajulu [19], 
2004
18 18
NSCLC (n = 15)
SCLC (n = 1)
Lung metastasis (n = 2)
0 0
Annema [20], 
2005
32 32
Squamous cell carcinoma (n = 4)
Adenocarcinoma (n = 7)
Large-cell undifferentiated carcinoma (n = 15)
SCLC (n = 4)
Giant-cell carcinoma (n = 1)
Non-Hodgkin lymphoma (n = 1)
0 1
Non-Hodgkin lymphoma (n = 1)
Paquin [21], 2005 15 13
NSCLC (n = 10)
Squamous cell carcinoma (n = 1)
Lung metastasis (n = 2)
2
No details reported (n = 2)
1
Squamous cell carcinoma (n = 1)
Sawhney [22], 
2006
19 18
No details reported (n = 18)
1
Pneumonia (n = 1)
6
No details reported (n = 6)
Hernandez [23], 
2007
17 17
NSCLC (n = 12)
SCLC (n = 4)
Carcinoid (n = 1)
0 0
Nguyen [24], 2011 24 NR NR NR
Songür [25], 2011 22 20
NSCLC (n = 14)
SCLC (n = 3)
Multiple myeloma (n = 1)
Lung metastasis (n = 2)
2
Schwannoma (n = 1)
No details reported (n = 1)
6
NSCLC (n = 1)
Multiple myeloma (n = 1)
Adenocarcinoma metastasis (n = 2)
Schwannoma (n = 1)
No details reported (n = 1)
Assisi [26], 2013 11 11
Squamous cell carcinoma (n = 4)
Adenocarcinoma (n = 5)
Undifferentiated carcinoma (n = 2)
0 0
Vazquez-
Sequeiros [27], 
2013
73 (final 
diagnosis 
available 
for 62)
61
NSCLC (n = 47)
SCLC (n = 8)
Lung metastasis (n = 6)
1
Hamartoma (n = 1)
2
NSCLC (n = 2)
Nasir [28], 2014 55 55
NSCLC (n = 47)
SCLC (n = 4)
Lung metastasis (n = 4)
0 3
NSCLC (n = 3)
Steinfort [29], 
2016
27 27
NSCLC (n = 3)
Squamous cell carcinoma (n = 4)
Adenocarcinoma (n = 12)
SCLC (n = 1)
Undifferentiated carcinoma (n = 1)
Lung metastasis (n = 5)
Marginal zone B-cell lymphoma (n = 1)
0 1
Marginal zone B-cell lymphoma (n = 1)
NSCLC, non-small cell lung carcinoma; SCLC, small cell lung carcinoma; NR, not reported.
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Study [Ref.], year Correct diagnosis
of malignancy
Total with 
malignancy
Sensitivity (95% CI)
Study = retrospective
Varadarajulu [19], 2004 18 18 1.00 (0.69 – 1.00)
Paquin [21], 2005 12 13 0.92 (0.61 – 0.99)
Hernandez [23], 2007 17 17 1.00 (0.68 – 1.00)
Assisi [26], 2013 11 11 1.00 (0.58 – 1.00)
Nasir [28], 2014 52 55 0.95 (0.84 – 0.98)
Steinfort [29], 2016 26 27 0.96 (0.78 – 0.99)
Meta-analysis 136 141 0.95 (0.90 – 0.98)
Study = prospective
Annema [20], 2005 31 32 0.97 (0.81 – 1.00)
Sawhney [22], 2006 12 18 0.67 (0.43 – 0.84)
Songür [25], 2011 16 20 0.80 (0.57 – 0.92)
Meta-analysis 59 70 0.83 (0.58 – 0.95)
Meta-analysis 195 211 0.92 (0.83 – 0.96)
Study [Ref.], year Correct 
diagnosis
Total EUS 
performed
Yield (95% CI)
Study = retrospective
Varadarajulu [19], 2004 18 18 1.00 (0.69 – 1.00)
Paquin [21], 2005 14 15 0.93 (0.65 – 0.99)
Hernandez [23], 2007 17 17 1.00 (0.68 – 1.00)
Nguyen [24], 2011 23 24 0.96 (0.76 – 0.99)
Assisi [26], 2013 11 11 1.00 (0.58 – 1.00)
Vazquez-Sequeiros [27], 2013 60 73 0.82 (0.72 – 0.89)
Nasir [28], 2014 52 55 0.95 (0.84 – 0.98)
Steinfort [29], 2016 26 27 0.96 (0.78 – 0.99)
Meta-analysis 221 240 0.93 (0.86 – 0.96)
Study = prospective
Annema [20], 2005 31 32 0.97 (0.81 – 1.00)
Sawhney [22], 2006 13 19 0.68 (0.45 – 0.85)
Songür [25], 2011 16 22 0.73 (0.51 – 0.87)
Meta-analysis 60 73 0.80 (0.56 – 0.93)
Meta-analysis 281 313 0.90 (0.82 – 0.95)
0 0.2 0.4 0.6 0.8 1.0
 Fig. 3. Yield of EUS-FNA for diagnosing intrapulmonary tumors located near or adjacent to the esophagus. The 
difference in yield between retrospective and prospective studies was not statistically significant ( p = 0.11). 
0 0.2 0.4 0.6 0.8 1.0
 Fig. 4. Sensitivity of EUS-FNA for diagnosing malignant intrapulmonary tumors located near or adjacent to the 
esophagus. The difference in sensitivity between retrospective and prospective studies was not statistically sig-
nificant ( p = 0.06). 
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 The limited number of studies with a low risk of bias 
and with scarce reporting prohibited us from taking the 
anticipated clinical sources of heterogeneity into account 
in the subgroup analyses.
 Complications 
 Three studies did not report whether there were any 
EUS-FNA-induced complications. Among the 8 studies 
that  did report this information, complications occurred 
in 5 of 256 patients (2.0%): 1 patient had self-limited se-
vere chest pain that required admission, but no cause was 
identified; 1 patient had self-limited hemoptysis; 1 patient 
had hemoptysis with aspiration pneumonia; and 2 pa-
tients had a pneumothorax ( Table 1 ). Mediastinitis, se-
vere bleeding without hemoptysis, or perforation of the 
esophagus were not reported, neither were technical 
complications with damage to the equipment.
 Discussion 
 The feasibility of EUS-FNA for obtaining an adequate 
tissue sample from intrapulmonary tumors located near 
or adjacent to the esophagus was first investigated in the 
early 2000s  [19] . It is surprising that the number of sub-
sequent evaluations on this topic is still low and mostly 
consists of retrospective studies with small sample sizes. 
The average yield of EUS-FNA for diagnosing intrapul-
monary tumors in this meta-analysis was 0.90, with a sen-
sitivity for diagnosing malignant tumors of 0.92, imply-
ing that EUS-FNA may be highly feasible for this purpose. 
However, several considerations need to be taken into ac-
count.
 Almost all of the included studies had a high risk of 
bias. Most of these studies retrospectively included pa-
tients that had undergone EUS-FNA for diagnosing an 
intrapulmonary tumor at their institution. Such noncon-
secutive inclusion is likely to lead to a highly selected sam-
ple of patients, perhaps with tumors that are relatively 
large and easy to reach by EUS-FNA. This will irrevocably 
lead to estimates of test performance that cannot be re-
produced in practice if applied to any patient with an 
 intrapulmonary tumor located near or adjacent to the 
esophagus. We considered this to be the major potential 
source of bias in our review. Not surprisingly, the average 
yield was 0.13 higher in the retrospective studies than in 
the prospective studies, although the confidence intervals 
were wide and the difference was not statistically signifi-
cant.
 Only 5 of the studies included explicitly reported on 
the number of patients in whom the tumor could not be 
visualized by EUS. For the remaining studies, it seems 
that they might have only included patients in their final 
analysis if the authors were able to actually visualize the 
tumor – or perhaps even only if they were able to take an 
adequate tissue sample from it with EUS-FNA. This prac-
tice would inflate estimates of yield and sensitivity. Again, 
we took this into account by performing subgroup analy-
ses, but in this case, we found no major differences in 
yield.
 The proportion of patients with malignancy across the 
included studies was unusually high, with a median of 
100%. We can only speculate about the reason for this, 
but it may, again, be related to the retrospective nature 
of most studies. The prevalence of malignant tumors is 
likely to be lower in practice.
 None of the included studies reported on the propor-
tion of patients that were considered eligible to undergo 
EUS-FNA for diagnosing an intrapulmonary tumor rela-
tive to the total number of patients presenting with an 
intrapulmonary tumor that required a tissue diagnosis 
during the recruitment period; the latter group also in-
cluded tumors located more peripherally. This is a factor 
that influences the potential usefulness of EUS-FNA in 
this setting, because a low proportion would imply that 
this indication rarely occurs.
 The statistical heterogeneity was substantial in our 
meta-analysis. Elements such as the experience of the en-
doscopist, the tumor size, and the location of the tumor 
with respect to the esophagus are likely to have a major 
influence on yield  [30, 31] . Due to the limited number of 
eligible studies and scarce reporting, we were unable to 
take these elements into account. It is expected that most 
studies were performed by highly experienced endosco-
pists, and that estimates of yield may not be immediately 
applicable to endoscopists with less experience. Most of 
the studies included were not specific about how close the 
tumors were located to the esophagus. All of this together 
may explain the large variety in yield.
 A substantial number of studies have evaluated the 
performance of EUS-FNA in diagnosing mediastinal tu-
mors and in mediastinal nodal staging in patients with 
lung cancer  [11] , and this application is now recommend-
ed in most clinical guidelines  [12–14] . However, the 
number of evaluations on the performance of EUS-FNA 
in diagnosing intrapulmonary tumors is clearly lagging 
behind  [10] . Based on our own experience, we believe 
EUS-FNA should be considered for those patients who 
present with an intrapulmonary tumor located adjacent 
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or near the esophagus, especially in cases where the alter-
native is surgery. This hypothesis is further supported by 
the findings of this review. However, also in cases in 
which EUS-FNA is used to establish a biopsy-based diag-
nosis, bronchoscopy remains the standard for obtaining 
a complete overview of the endobronchial situation, es-
pecially if patients are potentially eligible for surgical re-
moval of the intrapulmonary tumor.
 The general awareness among physicians that the 
esophagus can be a valuable route for the diagnosis and 
staging of lung cancer is still limited  [9, 32] . EUS-FNA is 
a safe procedure; complications only occurred in 2.0% of 
patients, and they were mostly mild. Since only 2 of 229 
patients had a pneumothorax due to EUS-FNA, routine 
performance of chest radiography after EUS-FNA of in-
trapulmonary tumors may not be indicated. EUS-FNA is 
also relatively inexpensive and provides the advantage 
that it can combine diagnosis and T-, N-, and M-staging 
with biopsies in a single procedure.
 EUS-FNA can be performed in an outpatient setting 
under local anesthesia. Using EUS-FNA, left and lower 
paraesophageal structures can be reached  [8] . As such, it 
is complementary to EBUS-TBNA, which provides access 
to structures close to the large airways on both sides  [9] . 
The advantages of EUS-FNA over EBUS-TBNA are that 
it is better tolerated by patients, that the transducer is in 
close contact with the target due to endoscopic suction on 
the esophagus, and that tissue sampling is not hampered 
by cartilage rings.
 Recent studies have also investigated the yield of linear 
EBUS-TBNA for diagnosing centrally located intrapul-
monary tumors in case the lung mass is located adjacent 
to the major airways  [33, 34] . A combined approach with 
EUS-FNA and EBUS-TBNA for mediastinal lymph node 
staging is implemented more and more in clinical prac-
tice  [9] . Such an approach could also be useful in the di-
agnosis of centrally located intrapulmonary tumors, as 
has recently been demonstrated  [35] . Especially the fact 
that increasing numbers of endoscopists perform both 
EBUS and EUS in a single session with an EBUS-scope 
(EUS-B) could facilitate the biopsy-proven diagnosis of 
intrapulmonary tumors and could lead to a highly effi-
cient, cheap, minimally invasive procedure with a limited 
patient burden. However, only in 1 of the included studies 
EUS-B was performed using an EBUS-scope; the yield 
and sensitivity in this study were in the same range as in 
studies that used an endoscope  [29] . Further research will 
need to confirm whether EUS-B indeed produces equal 
results for diagnosing intrapulmonary tumors. The ad-
vantages of using an EUS-scope over an EBUS-scope are 
that its ultrasonic window angle is larger, that the ultra-
sonic picture is of higher quality, that small structures are 
more easily visualized, and that the maneuverability of 
the needle is better.
 Larger prospective studies should be performed to 
evaluate whether our findings are reproducible. Such 
studies could assess the impact of tumor size and tumor 
location with regard to the esophagus on the performance 
of EUS-FNA.
 In conclusion, the findings of our review suggest that 
EUS-FNA is safe and has a high yield and sensitivity for 
diagnosing intrapulmonary tumors, but these findings 
are limited by the small number of high-quality studies. 
Future prospective studies are recommended to evaluate 
whether these findings are reproducible and to further 
refine the criteria for recommending EUS-FNA in this 
setting.
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